Emergent BioSolutions (EBS) Notes Payables (2016 - 2024)

Emergent BioSolutions' Notes Payables history runs 8 years deep, the most recent figure standing at $800000.0 for Q3 2024.

• On a quarterly basis, Notes Payables fell 99.81% year-over-year to $800000.0 in Q3 2024; TTM through Sep 2024 was $800000.0, a 99.81% decrease from a year earlier, with the FY2023 full-year figure at $413.7 million, down 56.78% from the prior year.
• Notes Payables eased to $800000.0 in Q3 2024 per EBS's latest filing, from $415.2 million in the prior quarter.
• Across five years, Notes Payables topped out at $957.3 million in Q4 2022 and bottomed at $800000.0 in Q3 2024.
• The 5-year median for Notes Payables is $31.6 million (2021), against an average of $231.0 million.
• Across the five-year window, Notes Payables surged 2929.43% in 2022 and slumped 99.81% in 2024, its largest moves.
• Year by year, Notes Payables stood at $33.8 million in 2020, then dropped by 6.51% to $31.6 million in 2021, then jumped by 2929.43% to $957.3 million in 2022, then slumped by 56.78% to $413.7 million in 2023, then tumbled by 99.81% to $800000.0 in 2024.
• Per Business Quant, the three latest EBS Notes Payables figures stand at $800000.0 (Q3 2024), $415.2 million (Q2 2024), and $459.2 million (Q1 2024).